Company Profile
Indivior Stock Price, News & Analysis
- Ticker:
- INDV
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom and listed in the U
Stock performance
38.67 USD (-0.15%)
Close
Last updated: August 6, 2026
3.98B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, INDV was little changed and closed at $38.67. No new same-company headline was identified in the current news window.
Company overview
Addiction Medicine
Indivior develops and commercializes medicines for substance-use disorders. Its strategy emphasizes long-acting formulations that support sustained treatment while reducing the burden and diversion risks associated with daily medication.
SUBLOCADE Franchise
SUBLOCADE is a monthly extended-release buprenorphine injection for opioid-use disorder and is the company’s primary commercial product. The formulation is administered by healthcare professionals and provides continuous buprenorphine exposure over the dosing interval.
Focused Portfolio Strategy
Indivior is concentrating resources on its marketed addiction franchise after deciding not to internally advance INDV-2000 and not to pursue Phase 3 development of INDV-6001. It retains potential U.S. commercial rights to a future viable product developed by the INDV-6001 licensor.
Future catalysts
Indivior’s catalysts are Sublocade execution, opioid-use-disorder growth, and any portfolio update that helps the company keep expanding. The company moves on steady commercial execution.
Recent news
- 01
- 02
- 03
- 04
Indivior to Participate in Upcoming Investor Conferences
Source: Indivior
- 05
Indivior Announces $175 Million Accelerated Share Repurchase
Source: Indivior
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Indivior (INDV)?
Indivior (INDV) most recently closed at 38.67 USD, a -0.15% move versus the previous session.
What is the market cap of Indivior (INDV)?
Indivior currently has a market capitalization of 3.98B USD on BioPharmSignal.
What does Indivior do?
Addiction Medicine Indivior develops and commercializes medicines for substance-use disorders. Its strategy emphasizes long-acting formulations that support sustained treatment while reducing the burden and diversion risks associated with daily medication. SUBLOCADE Franchise SUBLOCADE is a monthly extended-release buprenorphine injection for opioid-use...
On which exchange is INDV stock listed?
Indivior (INDV) is associated with NASDAQ, United Kingdom and listed in the U, Biopharma.
What is INDV-2000?
Focused Portfolio Strategy Indivior is concentrating resources on its marketed addiction franchise after deciding not to internally advance INDV-2000 and not to pursue Phase 3 development of INDV-6001.
Which conditions is Indivior targeting with INDV-2000?
Addiction Medicine Indivior develops and commercializes medicines for substance-use disorders. Its strategy emphasizes long-acting formulations that support sustained treatment while reducing the burden and diversion risks associated with daily medication. SUBLOCADE Franchise SUBLOCADE is a monthly extended-release buprenorphine injection for opioid-use...
How does Indivior describe recent progress with INDV-2000?
Indivior’s catalysts are Sublocade execution, opioid-use-disorder growth, and any portfolio update that helps the company keep expanding. The company moves on steady commercial execution.
What is INDV-6001?
Focused Portfolio Strategy Indivior is concentrating resources on its marketed addiction franchise after deciding not to internally advance INDV-2000 and not to pursue Phase 3 development of INDV-6001.